Melittin-K1 reverses multidrug resistance of human hepatocellular carcinoma BEL-7402/5-FU cells
10.3760/cma.j.cn113855-20200311-00180
- VernacularTitle:多肽Melittin-K1逆转人肝癌耐药细胞株BEL-7402/5-FU耐药性的研究
- Author:
Jian DONG
1
;
Shidi ZHAO
;
Tingyao CHEN
;
Mengyun KE
;
Yi LYU
Author Information
1. 西安交通大学第一附属医院精准外科与再生医学国家地方联合工程研究中心 陕西省再生医学与外科工程研究中心 710061；西安交通大学第一附属医院血管外科 710061
- From:
Chinese Journal of General Surgery
2020;35(11):882-886
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the mechanism by which Melittin-K1 reverses multidrug resistance of BEL-7402/5-FU cells.Methods:CCK-8 assay was used to evaluate the effect of Melittin-K1 on the growth of BEL-7402/5-FU cells and to explore whether Melittin-K1 could reverse the drug resistance of BEL-7402/5-FU cells. The expression of MDR1 mRNA level was detected by real-time fluorescence quantitative PCR assay. The flow cytometry was used to measure the expression of P-glycoprotein (P-gp) on the cell membrane surface and the accumulation of rhodamine-123 in cells.Results:Melittin-K1 significantly inhibited the growth of BEL-7402/5-FU cells in vitro in a time and dose-dependent manner. Melittin-K1 suppressed the level of MDR1 mRNA and inhibited the surface expression and function of P-gp in BEL-7402/5-FU cells. Conclusions:Melittin-K1, a novel peptide, exhibited the activity of reversing multidrug resistance of liver cancer cells.
